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ABSTRACT 
 Heart failure (HF) leads to frequent hospitalizations. The presence of re-
hospitalization risk among patientshospitalized for heart failure is important, especially 
hemodynamic instability and neurohormonal over activation. ARNI is needed to restore the 
balance of neurohormonal system in HF. PARADIGM-HF study provide insight on long term 
benefit of ARNI (i.e. sacubitril/valsartan) in ambulatory setting. How is the evidence of ARNI 
use for in-hospitalization phase of HF? PIONEER and TRANSITION showed that initiation of 
sacubitril/valsartan shortly after an ADHF event is feasible and well tolerated. In-hospital 
initiation of sacubitril/valsartan is associated with early and sustained improvements in 
biomarkers of cardiac wall stress and myocardial injury, indicating pathophysiological 
benefits in a wide range of HFrEF patients. 
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Introduction 
 Heart failure (HF) frequently leads 
to hospitalization. HF is one of the leading 
causes of hospitalization among patients 
aged > 65 years old in developed 
countries.1 Approximately 44% of all HF 
patients had hospital readmissions due to 
any causes within 1 year after discharge.2 
Length of hospital stay for HF is ranging 
from 5 to 10 days.3 In the United States of 
America, hospital readmission rate within 
30 days after discharge is 25%,4 
meanwhile in European countries, hospital 
readmission rate is 24% within 12 weeks 
after discharge. 5 
 
Discussion 
 Re-hospitalization risk among 
patients who were hospitalized for heart 
failure happened especially during 
patient’s transition of care period, which is 
a periodof shifting from close supervision 
by cardiologist team at the hospital to 
outpatient monitoring (which is less 
frequent compared to in-hospital 
monitoring) at home after discharge. Re-
hospitalization risk will remain high if there 
are hemodynamic imbalance and 
neurohormonal over activation.6,7 Nearly 
25% of HF patients will be readmitted 
within the first 30 days after discharge. 
The mortality rate during the 30-day 
period can be as high as 10%.6 The 
number of death associated with time after 
discharge is twice higher in the first 30 
days compared to 6 months after 
discharge. (Figure 1) 
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Figure 1. Mortality risk is twice higher within the first 30 days compared to 6 months after hospital 
discharge. 6 
 
 
ARNI on neurohormonal system 
balance in HF 
 Prospective comparison of ARNI 
with ACEI to Determine of impact on 
Global Mortality and morbidity in Heart 
Failure (PARADIGM-HF) study provides 
insight to long-term benefits of ARNI in 
outpatient setting. PARADIGM-HF study 
result showed that sacubitril/valsartan is 
superior to enalapril. In addition to it, 
PARADIGM-HF study showed reduction 
of mortality risk due to cardiovascular 
events or first HF hospitalization for 20%.8 
 Whether the initiation of 
sacubitril/valsartan therapy is effective and 
safe among hospitalized patients due to 
acute decompensated heart failure still 
remains unknown. The following study will 
acknowledge this question further.The 
Comparison of Sacubitril/Valsartan Versus 
Enalapril on Effect on NT-ProBNP in 
Patients Stabilized from an Acute Heart 
Failure Episode (PIONEER-HF) study 
examined heart failure patients with 
reduced ejection fraction (HFrEF) who 
were hospitalized due to acute 
decompensated heart failure in 129 
locations in the United States of America. 
After hemodynamic stabilization, eligible 
patients were randomized in a 1:1 fashion 
to sacubitril/valsartan group (targeted 
dose of 97 mg sacubitril with 103 mg 
valsartan twice daily) and enalapril group 
(targeted dose of 10 mg enalapril twice 
daily). The primary efficacy outcome is a 
time-averaged proportional change of n-
terminal pro-B-type natriuretic peptide 
(NT-proBNP) from the beginning of the 
study until week 4 and week 8. The main 
safety outcomes are worsening renal 
function, hyperkalemia, symptomatic 
hypotension, and angioedema. Of 881 
eligible patients who underwent 
randomization, 440 patients received 
sacubitril/valsartan while 441 patients 
received enalapril. Time-averaged 
reduction of NT-proBNP level was 
significantly greater insacubitril/valsartan 
group than enalapril group. Geometric 
mean ratio of values obtained at week 4 
and week 8 from baseline was 0,53 in 
sacubitril/valsartan group compared to 
0.75 in enalapril group (percent change, -
46.7% vs -25.3%; change ratio of 
sacubitril/valsartan group compared to 
enalapril group 0.71; 95% confidence 
interval (CI) 0.63 to 0.81; P<0.001). At the 
beginning of week 1 after drug initiation, a 
greater reduction of NT-proBNP level in 
sacubitril/valsartan group than in enalapril 
group was noted (change ratio 0.76; 95% 
CI 0.69 to 0.85). Worsening renal function, 
hyperkalemia, symptomatic hypotension, 
and angioedema did not differ significantly 
between both groups.9 (Figure 2 and 3).
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Figure 2. In-hospital initiation of sacubitril/valsartan decreases level of NT-pro BNP to a greater 
degree than enalapril. 6 
 
 
 
Figure 3. In-hospital initiation of Sacubitril/Valsartan reduces serious clinical outcomes compared to 
enalapril. 6 
 
 
In-hospital initiation of 
sacubitril/valsartan with HFrEF after 
hemodynamic stabilization was reported in 
the main outcome of TRANSITION study. 
In this study, 50% of patients achieved 
targeted dose of 200 mg twice a day in 10 
weeks, and more than 85% of patients 
could receive the targeted dose without 
interruption in both groups (pre-discharge 
and post-discharge) (Figure 4).10 
Predictors of success of 
sacubitril/valsartan up-titration to 200 mg 
were younger, healthier, de novo, and 
hypertensive patients. 
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Figure 4. Primary and secondary endpoints from TRANSITION study. 10 
 
 
Conclusion 
 Among heart failure patients with 
reduced ejection fraction who were 
hospitalized for acute decompensated 
heart failure, in-hospital initiation of 
sacubitril/valsartan was associated with 
greater reduction of NT-proBNP level than 
enalapril. Worsening renal function, 
hyperkalemia, symptomatic hypotension, 
and angioedema did not differ significantly 
between sacubitril/valsartan group and 
enalapril group. 
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